Cervical Spondylosis Treatment Global Market Report 2024

The cervical spondylosis treatment market size has grown strongly in recent years. It will grow from $5.51 billion in 2023 to $5.9 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth observed in the historic period can be attributed to factors such as an aging population, the increased prevalence of sedentary lifestyles, growing awareness of cervical spondylosis, expansion of healthcare infrastructure, and a rise in musculoskeletal disorders.

The cervical spondylosis treatment market size is expected to see strong growth in the next few years. It will grow to $7.51 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The anticipated growth in the forecast period can be attributed to increasing healthcare investments, the adoption of minimally invasive procedures, a rise in patient awareness and education, a growing focus on preventive measures, and the integration of telemedicine in treatment approaches. Major trends expected in the forecast period include the development of personalized treatment plans, the rise of non-surgical interventions, the creation of home-based therapeutic solutions, the integration of digital health platforms, and an emphasis on holistic and multidisciplinary approaches.

The growth of the cervical spondylosis treatment market is anticipated to be propelled by the increasing prevalence of this condition. Cervical spondylosis, a degenerative condition impacting the joints and discs in the neck's cervical spine, necessitates treatments aimed at alleviating pain, preserving activity levels, and preventing irreversible damage to the spinal cord and nerves. These treatments aim to enhance the overall well-being of individuals affected by cervical spondylosis. For instance, data from the American Academy of Orthopedic Surgeons in April 2021 revealed that over 85% of individuals aged 60 and above were reported to be affected by cervical spondylosis. Consequently, the escalating prevalence of this condition is a key driving force behind the growth of the cervical spondylosis treatment market.

The rise in healthcare expenditure is poised to fuel the expansion of the cervical spondylosis treatment market. Healthcare expenditure encompasses costs associated with providing health services, including aspects such as family planning, nutrition, and emergency medical assistance, with a primary focus on promoting health. Increased healthcare spending is instrumental in elevating patient awareness, facilitating early diagnosis, and enabling comprehensive management of cervical spondylosis. For instance, as outlined in the 2021–2030 National Health Expenditure (NHE) report published by the Centers for Medicare & Medicaid Services in March 2022, national health spending was projected to experience an average annual growth rate of 5.1% between 2021 and 2030, potentially reaching approximately $6.8 trillion by 2030. Consequently, the escalating healthcare expenditure serves as a significant driver propelling the cervical spondylosis treatment market.

Product innovation is emerging as a prominent trend within the cervical spondylosis treatment market, with major companies actively introducing innovative solutions to maintain their market positions. An illustration of this trend unfolded in March 2021 when Sleepsia, a US-based manufacturer renowned for innovative pillows, unveiled a novel cervical pillow tailored specifically to alleviate symptoms associated with cervical spondylosis, particularly neck pain. This new pillow is meticulously designed to strike a balance between firmness and softness, providing optimal support. Its ergonomic design facilitates a natural curvature for the neck, aiding in mitigating spinal issues that can arise from incorrect mattress or pillow usage. Furthermore, the pillow features hypoallergenic fabric that resists dust mites, addressing additional concerns related to allergies.


Prominent players in the market are strategically prioritizing the development of cutting-edge products, such as spinal support systems, to address the changing demands of patients and advancements in technology. Specifically, Aspen Medical Products, a US-based provider of solutions for pain and mobility management, unveiled the VRTX System in October 2023. This groundbreaking spine support system is meticulously crafted to offer comprehensive coverage from the cervical to sacrum regions. The VRTX System aims to revolutionize acute spinal care through its user-friendly prefabricated design and easily adjustable sizing, enabling healthcare professionals to promptly fit patients and stabilize their spines. This off-the-shelf solution is expected to reduce hospital stays, minimize complications, and enhance operational efficiency by optimizing time and inventory management. Featuring prefabricated components like CTO, TLSO, LSO, and CTLSO, each element within the VRTX System ensures optimal motion restriction and can be tailored to meet the specific needs of individual patients. This modular approach supports standardization of products and services within hospitals, promoting staff efficiency and elevating overall patient care.

In August 2023, ZimVie Inc., a US-based life sciences company operating in the dental and spine markets, announced an expansion of its collaboration agreement with Brainlab, a Germany-based leader in spine imaging, planning, and navigation solutions, incorporating robotic imaging, surgical assistance, and mixed reality technologies. This collaboration aims to merge ZimVie’s Vital and Virage fixation systems with Brainlab’s spine and trauma navigation technologies. By leveraging Brainlab's expertise, surgeons can effectively plan and execute spinal procedures, accurately position pedicle screws, and minimize radiation exposure, thereby enhancing the precision and safety of spinal surgeries.

Major companies operating in the cervical spondylosis treatment market report are Johnson & Johnson, Merck & Co Inc., AbbVie Inc., GlaxoSmithKline PLC, Medtronic PLC, C.H. Boehringer Sohn AG & Co. KG, Amgen Inc., Stryker Corporation, B. Braun SE, Zimmer Biomet Holdings Inc., UCB Pharma S.A., Integra LifeSciences Holdings Corp (Integra), Integra LifeSciences, NuVasive Inc., Globus Medical Inc., Orthofix Medical Inc., Aesculap Implant Systems LLC, Titan Spine Inc., Exactech Inc., SeaSpine Inc., RTI Surgical, Xtant Medical Holdings Inc., Zavation Medical Products LLC, Wenzel Spine Inc., Life Spine Inc., Spineology Inc., VGI Medical LLC, Dynamic Spine Inc., Synthes Holding AG, ZygoFix Ltd.

North America was the dominant region in the cervical spondylosis treatment market in 2023. The regions covered in the cervical spondylosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cervical spondylosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of cervical spondylosis treatment include medications, physical therapy, and surgery. Medications are substances used for diagnosing, preventing, treating, or managing various medical conditions and diseases. In the context of cervical spondylosis treatment, medications are employed to reduce inflammation and alleviate symptoms associated with the condition. These treatments cater to both youth and the elderly and are administered in different settings, such as hospitals, ambulatory surgical centers, and homecare.

The cervical spondylosis treatment market research report is one of a series of new reports that provides cervical spondylosis treatment market statistics, including cervical spondylosis treatment industry global market size, regional shares, competitors with a cervical spondylosis treatment market share, detailed cervical spondylosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the cervical spondylosis treatment industry. This cervical spondylosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cervical spondylosis treatment market consists of revenues earned by entities by providing physical therapy services, neck traction services, diagnosis, consultation, and surgical services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cervical spondylosis treatment market also includes the sales of nonsteroidal anti-inflammatory drugs, corticosteroids, and anti-seizure medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.